2023-10-26T11:09:31
POLICY ON NEW DRUG APPLICATION:
1. The content of New Drug Application (NDA) should be designed by the sponsor
to answer general question as follows:
i. Does the new drug provide a clinical benefit?
ii. Is the associated risk outweighing the benefits for the proposed indication?
iii. Can the product be manufactured ensuring quality and batch to batch consistency?
2. There should be a system that before an NDA is submitted to the CDSCO, the applicant should discuss with CDSCO wherein the applicant may present summary of the clinical, CMC, Pre-clinical, Clinical and any other information the
applicant considers relevant.
Have a question? Ask here!
Required fields are marked *